Trends & Forecasts

Ukrainian drug discovery has been disrupted by war. We spoke to leaders of its largest player about the domestic industry’s past, present, and future.

The war in Ukraine has massively impacted clinical trials. We spoke to one man tracking the disruption.

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

The Medicine Maker’s round up of the top news stories in the pharma industry in March.

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?

Nominations and voting for the Power List, Company of the Year Awards, and Innovation Awards ends on Thursday 17 March

Enveda Biosciences Founder Viswa Colluru shares the lessons he has learned whilst charting the vast terra incognita of nature’s chemical structure

Yvonne Duckworth lays out insights into Pharma 4.0 gleaned in a recent report by CRB. VR, AR, AI: is it more than just alphabet soup?

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

A report from Clarivate has tipped 7 drugs for potential blockbuster status in 2022. Here’s what makes them stand out.